Univ. of Maryland launches clinical trial of HIV vaccine candidate
“Maryland is one of the top science, bio-health, and research regions in the country and is home to some of the most brilliant minds in the world,” Rutherford said. “I am especially proud to help announce this first phase of a potential HIV vaccine that is being developed by a talented team at UMD. The (Gov. Larry) Hogan administration will continue to place a priority on supporting the Maryland universities, start-ups, and institutions that are making these groundbreaking discoveries.”
A team of researchers led by Robert Gallo will test the newly created HIV vaccine candidate. Gallo is best known for discovering the first human retroviruses, including the one that causes a certain branch of leukemia. His resume also includes developing the current HIV blood test and the co-discovery of AIDS being caused by HIV.
“Our HIV/AIDS vaccine candidate is designed to bind to the virus at the moment of infection, when many of the different strains of HIV found around the world can be neutralized,” Gallo said. “We believe this mechanism is a major prerequisite for an effective HIV preventive vaccine.”